Literature DB >> 6849304

Clonidine poisoning. A complex problem.

M Artman, R C Boerth.   

Abstract

Clonidine hydrochloride poisoning in children has become more frequent with increasing availability of this drug. We report four cases of accidental clonidine poisoning that demonstrate the various signs and symptoms of clonidine poisoning. The most frequent and significant toxic effects are depression of consciousness, bradycardia, hypotension, and respiratory depression. Ventilatory support must be available if apnea occurs. Bradycardia can be treated with atropine sulfate, epinephrine chloride, dopamine hydrochloride, or tolazoline hydrochloride. Hypotension is treated with intravenous fluids and dopamine, reserving tolazoline for refractory cases. Hypothermia is common but is of minor clinical significance. Paradoxical hypertension should be treated with tolazoline. Clonidine may not be detected in body fluids by routine toxicology-screening procedures, so poisoning should be suspected on clinical grounds.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6849304     DOI: 10.1001/archpedi.1983.02140280063018

Source DB:  PubMed          Journal:  Am J Dis Child        ISSN: 0002-922X


  4 in total

1.  Tolerance of the oral clonidine test in 75 pediatric patients.

Authors:  R De Angelis; C Pellini; C Petecca; F Uboldi; B di Natale
Journal:  J Endocrinol Invest       Date:  1988-05       Impact factor: 4.256

Review 2.  Clinical pharmacokinetics of clonidine.

Authors:  D T Lowenthal; K M Matzek; T R MacGregor
Journal:  Clin Pharmacokinet       Date:  1988-05       Impact factor: 6.447

Review 3.  Overdose of drugs for attention-deficit hyperactivity disorder: clinical presentation, mechanisms of toxicity, and management.

Authors:  Henry A Spiller; Hannah L Hays; Alfred Aleguas
Journal:  CNS Drugs       Date:  2013-07       Impact factor: 5.749

Review 4.  The role of systematic reviews in pharmacovigilance planning and Clinical Trials Authorisation application: example from the SLEEPS trial.

Authors:  Carrol Gamble; Andrew Wolf; Ian Sinha; Catherine Spowart; Paula Williamson
Journal:  PLoS One       Date:  2013-03-15       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.